ArticleFrontiers in immunology2026
BFJPM ameliorates OVA-induced food allergy in a murine model accompanied by gut microbiota remodeling.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BufeiJianpi Mixture (BFJPM) is a modified herbal formula developed from long-term clinical practice for the management of allergic constitution in children. To evaluate the therapeutic efficacy of BFJPM in an OVA-induced murine model of food allergy and to investigate its effects on the gut microbiota through integrated animal experiments, 16S rRNA gene sequencing, and network pharmacology.
methodsSixty 3-week-old female BALB/c mice were randomly assigned to six groups: negative control (NC), FA model, cetirizine, BFJPM-L, BFJPM-M, and BFJPM-H. An OVA-induced food allergy model was established. Therapeutic efficacy was assessed using allergy symptom scores, the V/C ratio of the small intestinal mucosa, and serum total IgE levels. Gut microbiota profiles were analyzed by 16S rRNA sequencing of intestinal contents. PICRUSt2 was used to predict microbial functional profiles, and network pharmacology was applied to identify key targets and pathways involved in BFJPM-mediated intervention.
resultsBFJPM reduced allergy symptom scores and serum total IgE levels and improved the V/C ratio in FA mice. NMDS analysis showed significant differences in gut microbiota composition among groups (stress = 0.141). BFJPM increased microbial richness and altered community structure, with enrichment of
conclusionBFJPM alleviated food allergy symptoms, reduced serum IgE levels, and improved intestinal mucosal integrity in OVA-induced FA mice. These effects were accompanied by remodeling of the gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.